Literature DB >> 23993817

Malignant pleural effusions: a review.

Justin M Thomas1, Ali I Musani.   

Abstract

Malignant pleural effusions are a cause of significant symptoms and distress in patients with end-stage malignancies and portend a poor prognosis. Management is aimed at symptom relief, with minimally invasive interventions and minimal requirement for hospital length of stay. The management options include watchful waiting if no symptoms are present, repeat thoracentesis, medical or surgical thoracoscopic techniques to achieve pleurodesis, pleuroperitoneal shunts, placement of tunneled pleural catheters, or a combination of modalities. To determine the best modality for management, patients must be assessed individually with concern for symptoms, functional status, prognosis, and their social and financial situations.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  End-stage malignancies; Malignant pleural effusions; Management; Review

Mesh:

Year:  2013        PMID: 23993817     DOI: 10.1016/j.ccm.2013.05.004

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  29 in total

Review 1.  Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis.

Authors:  Panwen Tian; Yongchun Shen; Chun Wan; Ting Yang; Jing An; Qun Yi; Lei Chen; Tao Wang; Ye Wang; Fuqiang Wen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Asymptomatic malignant pleural effusion: to observe or to manage.

Authors:  Sevak Keshishyan; Kassem Harris
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

3.  Letter To The Editor: Catheter Track Metastasis With Indwelling Pleural Catheter.

Authors:  Sara Zank; Elham Abboud; Wissam Jaber; Abdul Hamid Alraiyes
Journal:  Ochsner J       Date:  2017

4.  Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.

Authors:  Susana Herrera Lara; Estrella Fernández-Fabrellas; Gustavo Juan Samper; Josefa Marco Buades; Rafael Andreu Lapiedra; Amparo Pinilla Moreno; María Morales Suárez-Varela
Journal:  Lung       Date:  2017-06-27       Impact factor: 2.584

5.  Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.

Authors:  Katsuhiro Masago; Daichi Fujimoto; Shiro Fujita; Akito Hata; Reiko Kaji; Kyoko Ohtsuka; Chiyuki Okuda; Jumpei Takeshita; Nobuyuki Katakami
Journal:  Mol Clin Oncol       Date:  2014-11-19

6.  Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.

Authors:  Mei Feng; Jing Zhu; Liqun Liang; Ni Zeng; Yanqiu Wu; Chun Wan; Yongchun Shen; Fuqiang Wen
Journal:  Int J Clin Oncol       Date:  2016-12-18       Impact factor: 3.402

7.  Successful use of central venous catheters in the management of recurrent malignant pleural effusions: one new option.

Authors:  Abbas Yazdanbod; Azita Salehifar; Nasrollah Maleki; Shahram Habibzadeh; Zahra Tavosi
Journal:  Support Care Cancer       Date:  2015-01-10       Impact factor: 3.603

Review 8.  Treating Recurrent Pleural Disease: A Review of Indications and Technique for Chemical Pleurodesis for the Interventional Radiologist.

Authors:  Surbhi B Trivedi; Matthew Niemeyer
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

9.  Homocysteine: new tumor marker in pleural fluid.

Authors:  Jose D Santotoribio; Consuelo Cañavate-Solano; Angela Garcia-de la Torre; Luis Del Valle-Vazquez; Francisco Arce-Matute; Juan F Cuadros-Muñoz; Maria J Sanchez del Pino; Manuel J Bandez-Ruiz; Carmen Piñuela-Rojas; Santiago Perez-Ramos
Journal:  Tumour Biol       Date:  2015-05-09

10.  Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients.

Authors:  Wenxian Wang; Xiaowen Jiang; Yiping Zhang; Yong Song; Zhengbo Song
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.